CROI 2013: Researchers Discuss Advances in Tuberculosis Treatment
- Details
- Category: Tuberculosis (TB)
- Published on Monday, 11 March 2013 00:00
- Written by Keith Alcorn
A new two-drug combination of rifapentine and moxifloxacin can allow tuberculosis (TB) treatment to be taken just once-weekly during the 4-month continuation phase, according to a presentation at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta. A related meta-analysis found that rifampicin, a key drug in TB treatment, can be tolerated at much higher levels than used in current clinical practice, suggesting that higher doses might allow the treatment course to be shortened.
CROI 2013: Dolutegravir Helps Highly-resistant Treatment-experienced People on Failing ART
- Details
- Category: HIV Treatment
- Published on Friday, 08 March 2013 00:00
- Written by Liz Highleyman
The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for highly treatment-experienced people with resistance to 2 or more antiretroviral drug classes, researchers reported in a poster presented at the20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.
CROI 2013: New Antiretroviral Agents: Cenicriviroc [VIDEO]
- Details
- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
- Written by Gregory Fowler
Tobira's cenicriviroc, a dual CCR5 and CCR2 receptor blocker with both antiviral and anti-inflammatory action, appears effective and better tolerated than some currently approved drugs, according to data presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Adding Telaprevir Ups Acute Hepatitis C Cure Rate for HIV+ Men [VIDEO]
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Friday, 08 March 2013 00:00
- Written by Gregory Fowler
Adding telaprevir (Incivek) to pegylated interferon/ribavirin for treating HIV positive men with acute sexually transmitted hepatitis C considerably shortens the duration of therapy and improves the likelihood of a cure, according to study findings presented this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: New Pro-drug Tenofovir Alafenamide Appears Equally Effective but Better Tolerated
- Details
- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
- Written by Liz Highleyman
Tenofovir alafenamide fumarate, or TAF (formerly GS-7340), a new pro-drug of the widely used NRTI tenofovir, reaches cells harboring HIV more easily than the older disoproxil fumarate (TDF), allowing for similar antiviral efficacy with smaller doses and with less adverse effect on kidneys and bones,researchers reported Tuesday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
More Articles...
- CROI 2013: Can People with Resistant HIV Omit NRTIs When Switching to a New Regimen? [VIDEO]
- CROI 2013: HIV Treatment for Children Safe and Highly Effective without Laboratory Monitoring
- CROI 2013: New Tenofovir Alafenamide Looks Easier on Kidneys [VIDEO]
- CROI 2013: Monthly Injectable and Tenofovir Vaginal Ring Protect Monkeys against Infection
Web Design and Development by